Neurontin Liability Suits Take Personal Twist With Witness Intimidation Charge
Executive Summary
When you hear about witness intimidation in a drug case, you usually don't think an Rx kingpin is involved. But Pfizer's use of a private detective in the first Neurontin liability case to go to trial has produced a behind-the-scenes drama that could spill over into subsequent litigation
You may also be interested in...
Pfizer To Monitor Off-Label Drug Use Under Neurontin Settlement
Pfizer will provide periodic reports to the HHS Inspector General about off-label use trends for its products under the May 13 settlement of an investigation into the company's promotion of Neurontin
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials